Drugs / GH56
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06796699 | Mar 2025 → Dec 2027 expected | — | Suzhou Genhouse Bio Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GH56 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06796699 ↗ |
| Route | Oral | “GH56 capsule for oral administration at specified doses on scheduled days.” NCT06796699 ↗ |